Market Overview

Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics

Pfizer Analyst Says COVID-19-Driven Rally Not Backed By Vaccine Economics

Pfizer Inc. (NYSE: PFE) and BioNTech SE – ADR announced an agreement with the U.S. government Wednesday to supply an initial consignment of 100 million doses of the coronavirus vaccine the companies are developing in the event of future emergency use authorization or full approval for the shot. 

US Government Deal Positive For Pfizer: Pfizer's deal is positive for the nation as well as the company, BofA Securities analyst Geoff Meacham said in a note. 

The U.S. government has the optionality to acquire an additional 500 million doses the analyst said. Assuming a two-dose regimen, 600 million doses could cover over 90% of the U.S. population, he said. 

For Pfizer, the vaccine news is a positive development, Meacham said.

That said, the analyst does not see the vaccine programs as being fully derisked is looking ahead to additional data as Phase 3 trials get underway.

Pfizer's Vaccine Economics: At the $20 price point implied by the U.S. government's contract value and assuming a 50-50 gross profit split between Pfizer and BioNTech, Meacham expects the vaccine to be helpful to Pfizer's P&L.

This is especially true as company contends with portfolio risks that include the adjuvant Ibrance failure, recent pipeline programs that failed to stand apart from competition and the Eliquis patent ruling, the analyst said. 

Pfizer shares have added about $30 billion in value since their recent low in June, mainly on COVID-19 news. The valuation implies about 1.5 billion doses sold at the $20 price point, Meacham said. 

To justify the valuation, Pfizer may have to sell about 6 billion doses at a 50% margin, according to BofA — more than the sell-side firm's assumed number of patients treated worldwide through 2030 .

PFE Rating, Price Action: Meacham maintained a Neutral rating on Pfizer with a $38 price target. 

At last check, Pfizer shares were down 0.18% at $38.49. 

Related Links:

Intel, Texas Instruments To Kickstart Chip Earnings With 'Better-Than-Feared' Results

Nvidia Analysts See Multibillion-Dollar Opportunity In Automated Driving Deal With Mercedes-Benz

Latest Ratings for PFE

Jul 2020Morgan StanleyMaintainsEqual-Weight
Jul 2020UBSMaintainsNeutral
Jul 2020SVB LeerinkMaintainsMarket Perform

View More Analyst Ratings for PFE
View the Latest Analyst Ratings


Related Articles (PFE)

View Comments and Join the Discussion!

Posted-In: BofA SecuritiesAnalyst Color Biotech Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

NVCRWells FargoDowngrades
EDMorgan StanleyMaintains75.0
ABEOB. Riley FBRInitiates Coverage On5.0
AMBABerenbergInitiates Coverage On67.0
ARGOCompass PointInitiates Coverage On41.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at